⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 14 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth

Hilary A. Kenny Carman Ka Man Ip Lucy Kelliher Tejas Samantaray Kasjusz Kordylewicz Rachael Hoffmann Sarah Rauch Beatrice Malacrida Sophie L.P. Skingsley Frances R. Balkwill Chiara Battistini Ugo Cavallaro Wolf R. Wiedemeyer Ernst Lengyel

View at Publisher

Ask AI

Bookmark

Share

Key Points

Combining navitoclax and ym155 with carboplatin effectively reduces ovarian cancer tumor growth.
Navitoclax and ym155 promote autophagy, enhancing the effects of carboplatin on cancer cells.
The study identifies significant induction of apoptosis via navitoclax and ym155 in cancer treatment.
These findings indicate potential new combinations for treating ovarian cancer, improving therapeutic options.

Implication

Combined treatment with navitoclax, ym155, and carboplatin effectively inhibits ovarian cancer growth, suggesting new therapeutic strategies.

Abstract

Navitoclax and YM155 induce autophagy and Navitoclax, YM155, and Omipalisib induce apoptosis

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kenny et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02e8 https://doi.org/10.1158/1535-7163.29759698

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
2Supplemental Figure 9 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
3Supplemental Figure 11 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
4Supplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
5Supplemental Figure 1 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025

More related papers

Supplemental Figure 5 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplementary Data from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 4 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025